Literature DB >> 2295945

Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation.

R L Wahl1, J Wissing, R del Rosario, K R Zasadny.   

Abstract

Autoradiolysis of therapeutic doses of monoclonal antibodies can occur rapidly, limits their shelf life and makes onsite radiolabeling a near-necessity. We evaluated freezing of three different 131I-labeled murine monoclonal antibodies at -70 degrees C, immediately following radiolabeling, as a method of diminishing autoradiolysis, and of preserving immunoreactivity. Freezing greatly limits the ability of radiation-induced free radicals to diffuse in solution and thus produce radiolytic damage. By freezing at -70 degrees C autoradiolytic damage of immunoreactivity of three different 131I monoclonal antibodies could be largely eliminated, in contrast to the 80-90% losses in immunoreactivity seen with storage at 4 degrees C for a period of 1 to 12 days. Reduced in vitro deiodination rates are also seen for frozen antibodies. Limited studies with 125I-labeled antibodies indicate autoradiolysis does occur, though at a slower rate per mCi than for 131I, and that this process is also retarded by freezing. Freezing may be valuable while quality control procedures are performed following radiolabeling as well as if temporary storage or shipment of radioantibodies prior to patient dosing is undertaken. While the approach should be validated for each antibody studied, freezing of therapeutic doses of monoclonal antibodies appears to be a simple and effective approach to the problem of autoradiolysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295945

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.

Authors:  Maren Bienert; Ingrid Reisinger; Stefanie Srock; Beatrice I Humplik; Christel Reim; Thomas Kroessin; Norbert Avril; Antonio Pezzutto; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-04       Impact factor: 9.236

Review 2.  Animal models and molecular imaging tools to investigate lymph node metastases.

Authors:  Elliot L Servais; Christos Colovos; Adam J Bograd; Julie White; Michel Sadelain; Prasad S Adusumilli
Journal:  J Mol Med (Berl)       Date:  2011-05-10       Impact factor: 4.599

3.  In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.

Authors:  Flavio Forrer; Jianhua Chen; Melpomeni Fani; Pia Powell; Andreas Lohri; Jan Müller-Brand; Gerhard Moldenhauer; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

4.  Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts.

Authors:  F E Yang; R S Brown; K F Koral; A C Clavo; G A Jackson; R L Wahl
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.

Authors:  Tobias Weber; Benedikt Bötticher; Walter Mier; Max Sauter; Susanne Krämer; Karin Leotta; Armin Keller; Anne Schlegelmilch; Ludger Grosse-Hovest; Dirk Jäger; Uwe Haberkorn; Michaela A E Arndt; Jürgen Krauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

6.  68Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers.

Authors:  Henri Baudhuin; Julie Cousaert; Philippe Vanwolleghem; Geert Raes; Vicky Caveliers; Marleen Keyaerts; Tony Lahoutte; Catarina Xavier
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10

7.  Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.

Authors:  S Kinuya; K Yokoyama; H Tega; T Hiramatsu; S Konishi; W Yamamoto; N Shuke; T Aburano; N Watanabe; T Takayama; T Michigishi; N Tonami
Journal:  Jpn J Cancer Res       Date:  1998-08

8.  Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation.

Authors:  Jessica Bridoux; Katrijn Broos; Quentin Lecocq; Pieterjan Debie; Charlotte Martin; Steven Ballet; Geert Raes; Sara Neyt; Christian Vanhove; Karine Breckpot; Nick Devoogdt; Vicky Caveliers; Marleen Keyaerts; Catarina Xavier
Journal:  Biomolecules       Date:  2020-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.